Deprince Race Zollo Inc adds St. Jude Medical (STJ) to its portfolio

St. Jude Medical (STJ) : Deprince Race Zollo Inc added new position in St. Jude Medical during the most recent quarter end. The investment management firm now holds 1,429,964 shares of St. Jude Medical which is valued at $107,390,296 , the company said in a statement filed on May 2, 2016 with the SEC.St. Jude Medical makes up approximately 2.10% of Deprince Race Zollo Inc’s portfolio.

St. Jude Medical closed down -0.41 points or -0.54% at $75.1 with 35,89,843 shares getting traded on Friday. Post opening the session at $75.2, the shares hit an intraday low of $74.94 and an intraday high of $75.59 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Wedge Capital Management L L Pnc sold out all of its stake in STJ during the most recent quarter. The investment firm sold 603,750 shares of STJ which is valued $45,341,625. Emerald Advisers Incpa added STJ to its portfolio by purchasing 27,873 company shares during the most recent quarter which is valued at $2,123,923. St. Jude Medical makes up approx 0.10% of Emerald Advisers Incpa’s portfolio.Quadrant Capital Group reduced its stake in STJ by selling 57 shares or 5.58% in the most recent quarter. The Hedge Fund company now holds 964 shares of STJ which is valued at $73,457. St. Jude Medical makes up approx 0.05% of Quadrant Capital Group’s portfolio. Boston Family Office sold out all of its stake in STJ during the most recent quarter. The investment firm sold 4,550 shares of STJ which is valued $346,710.

On the company’s financial health, St. Jude Medical reported $0.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.88. The company had revenue of $1448.00 million for the quarter, compared to analysts expectations of $1437.78 million. The company’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.93 EPS.

Many Wall Street Analysts have commented on St. Jude Medical. St. Jude Medical was Downgraded by Credit Suisse to ” Neutral” on May 3, 2016. St. Jude Medical was Downgraded by Morgan Stanley to ” Equal-Weight” on May 2, 2016. St. Jude Medical was Downgraded by Needham to ” Hold” on Apr 29, 2016.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.